Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 0.50 0.40 0.55 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 3.2 -1.5 - 3

Motif Bio Share Discussion Threads

Showing 8926 to 8946 of 9100 messages
Chat Pages: 364  363  362  361  360  359  358  357  356  355  354  353  Older
DateSubjectAuthorDiscuss
13/1/2021
09:09
Billy - go back and watch the Proactive interview just before the FDA decision came out. He pointedly makes reference to the 3 options and all bases covered. I have watched it so many times You can even look out for the cheeky grin when saying...as we have always said they may ask for more data...when he talks about the 3rd option. Shifty looking smile that isn’t when you watch? Of course he had said the FDA didn’t ask for more clinical trials in the webcast of the 19th Feb 2019 leaving everyone thinking that it was a solvable issue but we ended up with full phase 3 trials!! Funny old world the Complete Response Letter and it’s interpretation isn’t? Look forward to requesting it for my book at the end of this month. Cost a few Bob in court no doubt but we deserve to see what it said don’t we?
scottdavid70
13/1/2021
09:02
12 business days left and the comfort of having Dr Lumsdens promise that he has all bases covered fills me with so much confidence. All bases covered means he is able to protect your investment based on his guidance so that’s great news for us with less time remaining than possible for a General Meeting to be called. What scenario could possibly work out to be bad for investors seriously with that type of guarantee attached to your money??
scottdavid70
13/1/2021
09:01
I'm not sure what you mean by "two out of three of the easier options to approval". As I understood it, the phase 3 trial collected the data the FDA told the board they would want and the trial was successful. But after they applied for approval the FDA moved the goalposts. What were the other options or routes to approval?
bi11y ray va1entine
13/1/2021
08:42
Remember if we do get a last minute vote to call your nominee bank/institution so you can tell them how you want to vote via the proxy form of one is produced. Might be a lastminute.com vote if the deal obliterates shareholders further and potentially enriches this shower further so make sure you can vote to Stoke that happening if nothing else. I am primed and ready with double digit millions of votes to turn the tide of greed into wealth for the righteous hard working ordinary investor who has been lead down a path of financial Armageddon
scottdavid70
13/1/2021
07:16
So the million pence question surrounding this shower of a Board is about to be answered. It’s really very simple: To leave it this late to announce the RTO means it’s either been the most competitive RTO in the history of RTO’s or it’s such a bad deal for existing shareholders they have left it this late so they can say it’s this deal or nothing. Which one does everyone think it is? Any guesses which one I think it is?......
scottdavid70
12/1/2021
16:05
Nope he meant it in the event that Iclaprim wasn’t given 2 out of the 3 easier options to approval that he still had the third base, another trial, covered. As we know that was simply not true
scottdavid70
12/1/2021
10:08
Is there a reason you think the "All bases covered" claim wasn't just an honest mistake? I don't know as much about this as you do. But didn't the company do exactly what the FDA said they should right up until the response?
bi11y ray va1entine
11/1/2021
19:10
Don’t panic at all. Remember DR LUMSDEN and you can always trust a DR said he has “all bases covered” Chill and enjoy the legend that is the Lumsden
scottdavid70
11/1/2021
15:11
The directors will get a share deal.. do think they will want the share price to go down or UP.
petersmith6
11/1/2021
13:32
Some people have the silly idea that this will rise like a Phoenix from the ashes. It will in fact sink like the Titanic, in this case never to be seen or heard from again.
perfectstorm
11/1/2021
10:34
It’s like the guy they are writing about here didn’t decimate Motif shareholders and was a unqualified success. Absolutely remarkable and equally wrong
scottdavid70
11/1/2021
06:22
Are Motif long suffering shareholders going to get the vote they were promised?
scottdavid70
11/1/2021
02:49
There has been an RTO and have been renamed the LSE Inaction Group.
lithological heterogeneities
10/1/2021
21:25
What’s happened to the LSE Action Group?
smcl
10/1/2021
20:04
Certainly don’t think it’s beyond the realms of possibilities that the recent update was simply to stop shareholders calling a General Meeting. Robblertwo was calling Walbrook saying we easily had the 5% and was wanting to call a GM to get the BOD to answer the tough questions they have run from these past 2 years. Given Greedy Graham was in the running for the new CEO job, how is quite beyond me after what he has done here, it would have been most untimely for him if a GM by livid,long suffering shareholders had been called. Wouldn’t have looked good on his CV at that stage but his resume has been nicely edited when taking into account the recent press release for his new venture of trousering ordinary, hard working investors cash. Sorry but the update and the next update being in the second half of the month just makes it the cherry on top of this sorry saga. Even at the end it seems they promised more than they can deliver.
scottdavid70
10/1/2021
15:00
Hey BIOMARK investors your new CEO took the company from a 40p a share to at one point 0.1p and got delisted at 0.5p. Wishing you all the best over there. You may need it What’s his starting salary??
scottdavid70
10/1/2021
09:23
Agree Scott- that’s the problem with LinkedIn profile- while paper doesn’t refuse ink- computers don’t refuse exaggeration- who’s to correct the profile? You can put in what you like - leave out the bits you don’t like etc etc
smcl
10/1/2021
06:34
It’s phenomenal in the article about Graham Lumsdens new job and the press release attached to it that there is no mention of his FAILURE to get Iclaprim approved. How to airbrush out your history or what!!! Good luck to the BIOMARK investors they are going to need it!! hxxps://www.businesswire.com/news/home/20210106005108/en/BIOMARCK-Appoints-Graham-Lumsden-as-President-and-Chief-Executive-Officer
scottdavid70
08/1/2021
19:48
But I won’t be so will continue with the book etc once my assumptions are confirmed
scottdavid70
08/1/2021
15:17
If it turns out you're wrong does that mean you'll finally stop going on about it?
bi11y ray va1entine
08/1/2021
07:06
Yup this is going to be presented as a fait accompli this month. We won’t have a say and the two men charged with looking after shareholders interests will leave with a hefty wad of cash. So so wrong on so many levels.
scottdavid70
Chat Pages: 364  363  362  361  360  359  358  357  356  355  354  353  Older
ADVFN Advertorial
Your Recent History
LSE
MTFB
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210225 11:33:59